Angeles Secord, MD
Enriched profileProfessor of Obstetrics and Gynecology, Division of Gynecologic Oncology · Duke University School of Medicine
Angeles Secord is Professor of Obstetrics and Gynecology, Division of Gynecologic Oncology at Duke University School of Medicine. OpenAlex indexes 595 publications with 41,092 citations (h-index 72); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Gynecologic Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 15 Oct 2026
Angeles Alvarez Secord, MD, is Professor of Obstetrics and Gynecology, Division of Gynecologic Oncology at Duke University School of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology (Duke Cancer Institute). The public record shows 595 publications with 41,092 citations (h-index 72), centered on Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 18 companies, 4 NIH-funded awards (2014–2025).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Ovarian cancer diagnosis and treatment
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 18 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 227.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- Signatera Assessment in Early-Stage Endometrial Cancer
Sponsor: Natera, Inc.
- BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
Sponsor: BioMimetix JV, LLC
Industry payments
Updated 15 Oct 2026
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202514 payments$14,462openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20259 payments
- Daiichi Sankyo Inc.Program year20256 payments
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
100%Progestin100%Megestrol Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 15 Oct 2026
4 NIH research awards on record, funded 2014–2025 per NIH RePORTER. The latest:
Congress activity
Updated 15 Oct 2026
75 congress contributions (2003–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Addressing barriers to FRα-directed therapy integration in platinum-resistant ovarian cancer: A multi-phase, community-informed initiative.
ASCO Annual Meeting
ASCO2026Co-author - Azenosertib plus paclitaxel for platinum-resistant ovarian cancer: Results from a phase 1b study.
ASCO Annual Meeting
ASCO2026Co-author - Abstract 4195: Efficacy of tumor treating fields (TTFields) applied with cisplatin and paclitaxel in cervical cancer cells
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.
Clinical cancer research
Clinical Trial2026 - Suppression of Paclitaxel-Induced Neuropathy and Ovarian Tumor Growth by Mn Porphyrin, MnTnBuOE-2-PyP(5+) (BMX-001).
Oxidative medicine and cellular longevity
Article2025 - Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Journal of clinical oncology
Clinical Trial2024 - Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Journal of clinical oncology
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome AnalyticsArticle4,006 citations2018
- 02Oncogenic Signaling Pathways in The Cancer Genome AtlasArticle3,421 citations2018
- 03Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of CancerArticle2,747 citations2018
- 04Comprehensive Characterization of Cancer Driver Genes and MutationsArticle2,539 citations2018
- 05Machine Learning Identifies Stemness Features Associated with Oncogenic DedifferentiationArticle2,378 citations2018
Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/angeles-secord-md-dd409caa
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/angeles-secord-992371234
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Angeles-Alvarez-Secord-39118821
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/DukeCancerInstitute/posts/dcis-angeles-alvarez-secord-md-and-emma-rossi-md-spoke-at-this-years-annual-glob/1273084611520197
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Facebook
facebook.com/GSK/posts/gynecologic-oncologist-dr-angeles-alvarez-secord-joined-endometrialcancer-surviv/1276439414527441
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗ - Facebook
facebook.com/SGO.org/posts/angeles-alvarez-secord-md-mhsc-former-sgo-president-served-on-national-academies/1024380509731073
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/sgo_org/p/DD2RrHFT3Pb
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- Board Certified
American Board of Obstetrics and Gynecology - Obstetrics & Gynecology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗ - Board Certified
American Board of Obstetrics and Gynecology - Gynecologic Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obgyn.duke.edu ↗
- Chair
Scholar Committee, American Association of Obstetricians and Gynecologists Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obgyn.duke.edu ↗ - Board Member
GOG Foundation
- Co-Chair
Education and Mentoring, GOG Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗ - Vice Chair
New Investigator Committee, NRG Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗ - Fellow
American College of Obstetricians and Gynecologists (FACOG)
- Director of Gynecologic Oncology Clinical Trials; Associate Director of Clinical Research
Gynecologic Oncology, Duke Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗
- Honored for Exceptional Service
American Association of Obstetricians and Gynecologists Foundation
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obgyn.duke.edu ↗ - Graduated Alpha Omega Alpha (AOA) with honors
University of Washington School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medschool.duke.edu ↗
Secondary affiliations
appointments beyond the home institution- Member
Duke Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗ - Principal Investigator
NRG Oncology at Duke Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologytoday.researchtopractice.com ↗
- Video interview
"Dr Angeles Alvarez Secord on 'Exciting' Responses With Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer" (AJMC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
William Kraus, MD
Duke University School of Medicine
Virginia Kraus, MD, PhD
Duke University School of Medicine
Neal Ready, MD
Duke University School of Medicine
Robert Mentz, MD
Duke University School of Medicine
Baha Sibai, MD
McGovern Medical School at UTHealth Houston
Robert Coleman, MD
Vaniam Group
Kathleen Moore, MD
University of Nebraska Medical Center
Bradley Monk, MD
Florida Cancer Specialists & Research Institute